Hoth Therapeutics Secures US patent for Alzheimer's treatment

Hoth Therapeutics, Inc., a company in the clinical stage of biopharmaceuticals that specializes in creating new treatments, is excited to share the news of receiving a US patent for their cutting-edge Alzheimer's treatment, HT-ALZ. This significant patent protects the company's unique treatment method, as Hoth speeds up preparations for clinical trials.

HT-ALZ is a significant advancement in the treatment of Alzheimer's disease, focusing specifically on the Substance P/Neurokinin-1 Receptor pathway. This pathway is understood to have an important function in neuroinflammation, which is being more widely acknowledged as a key factor in the advancement of Alzheimer's disease. Preclinical research has demonstrated encouraging outcomes, such as decreased neuroinflammation and notable enhancements in cognitive abilities like memory and learning.

The patent strengthens Hoth's position in the advancement of Alzheimer's treatments and prepares for the upcoming stage of human trials. Development of HT-ALZ for these tests is currently in progress, aiming to move this encouraging therapy to patients quickly.

Once the formulation phase is finished, Hoth Therapeutics will begin to plan clinical trials to confirm the effectiveness of HT-ALZ in humans. The future trials will concentrate on showing the drug's ability to be safe, well-tolerated, and effective in reducing or reversing the cognitive deterioration linked to Alzheimer's disease.

Robb Knie, CEO of Hoth Therapeutics, commented, "This patent marks a significant achievement for Hoth as we progress HT-ALZ from the lab to clinical development. The preclinical data on neuroinflammation reduction and cognitive improvement offer great hope, and we are excited to take the next critical steps toward delivering a potentially life-changing therapy to Alzheimer's patients."